Enoximone

Cardiac Therapy · Phosphodiesterase type-3 inhibitor

Indications

Congestive heart failure where cardiac output reduced and filling pressures increased.

Dosage

Adults: By slow intravenous injection (rate not exceeding 12.5 mg/min), diluted before use, initially 0.5-1 mg/kg, then 500 mcg/kg every 30 min until satisfactory response or total of 3 mg/kg given; maintenance, initial dose of up to 3 mg/kg may be repeated every 3-6 hr as required. By intravenous infusion, initially 90 mcg/kg/ min over 10-30 min, followed by continuous or intermittent infusion of 5-20 mcg/kg/min.

Adverse Effects

Ectopic beats, less frequently ventricular tachycardia or supraventricular arrhythmias (more likely in patients with pre-existing arrhythmias); hypotension; also headache, insomnia, nausea and vomiting, diarrhoea; occasionally, chills, oliguria, fever, urinary retention; upper and lower limb pain.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Risk cannot be ruled out. Lactation: Caution advised or effect undetermined. Precautions: Heart failure associated with hypertrophic cardiomyopathy, stenotic or obstructive valvular disease or other obstruction; monitor blood pressure, heart rate, ECG, central venous pressure, fluid and electrolyte status, renal function, platelet count, hepatic enzymes; avoid extravasation; renal impairment.

Interactions

Anagrelide.

Pharmacokinetics

Absorption: Absorbed from the GI tract. Metabolism: Hepatic. Bioavailability: Oral: 50%. Half-life elimination: Healthy subjects: 1-4 hrs. Patients with heart failure: 3-8 hrs. Excretion: Urine (mainly as metabolites).

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.